Cel-Sci Corporation (NYSE American: CVM) is a biotechnology company that researches drugs for the treatment of cancer, autoimmune, and infectious diseases through the development of immunotherapy products.
Cel-Sci’s main product is Multikine, an immunotherapeutic agent that stimulates the body’s immune system. Multikine recently completed Phase III trials with the FDA. The therapeutic is also known as Leukocyte Interleukin Injection (LI). Multikine was in Phase II testing of patients with head and neck cancer during the early 2000s, showing that it had the ability to reduce tumor growth.
In 2007, the US FDA cleared Phase 3 trials for Multikine and it was designated an orphan drug to be used in neoadjuvant squamous cell carcinoma of the head and neck.